Proteomic biomarker predicts therapeutical effects of oxaliplatin combining with fluoropyrimidine in metastatic gastric cancer patients by the SELDI-proteinchip platform

Hepato-Gastroenterology

Volumn 60, Issue 127, 2013, Pages 1800-1804

  Yu, Zhuo ^a   Yu, Jie Kai ^a   Fang, Xue Feng ^a   Yuan, Ying ^a   Shen, Hong ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Chemotherapy; Gastric cancer; Proteomic pattern; SELDI TOF MS

Indexed keywords

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; INDIVIDUALIZED MEDICINE; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM PROTEINS; ORGANOPLATINUM COMPOUNDS; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROTEIN ARRAY ANALYSIS; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; STOMACH NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84893900037     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge13112     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, et al.: Cancer Statistics, 2008. Cancer J Clin 2008; 58:71-96. (Pubitemid 351521864)
2. Mari E, Floriani I, Tinazzi A, et al.: Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD. Ann Oncol 2000; 11(7):837-843.
3. Khushalani NI: Phase I and II clinical trials for gastric cancer. Surg Oncol Clin N Am 2012; 21(1):113-128.
4. Park DJ, Lee HJ, Kim HH, et al.: Predictors of operative morbidity and mortality in gastric cancer surgery. Br J Surg 2005; 92:1099-1102. (Pubitemid 41284874)
5. Ha TK, Jung MS, Lee KH, et al.: The effect of adjuvant chemotherapy on Stage IV (T4N1-3M0 and T1-3N3M0) gastric cancer. Cancer Res Treat 2009; 41(1):19-23.
6. Janunger KG, Hafstrom L, Nygren P, Glimelius B; SBU-group: A Systematic overview of chemotherapy effects in gastric cancer. Acta Oncologica 2001; 40(2/3):309-326. (Pubitemid 32588125)
7. Sumpter K, Harper-Wynne C, Cunningham D, et al.: Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer 2005; 92(11):1976-1983. (Pubitemid 40897418)
8. De Bock M, de Seny D, Meuwis MA, et al.: Challenges for Biomarker discovery in body fluids using SELDI-TOF-MS. J Biomed Biotechnol 2010; 2010:906082.
9. Kojima T, Yoshikawa K, Saga S, et al.: Detection of elevated proteins in peritoneal dissemination of gastric cancer by analyzing mass spectra data of serum proteins. J Surg Res 2009; 155(1):13-17.
10. Pietrowska M, Polanska J, Marczak L, et al.: Mass spectrometry-based analysis of therapy-related changes in serum proteome patterns of patients with early-stage breast cancer. J Transl Med 2010; 8:66.
11. Ocak S, Chaurand P, Massion PP: Mass Spectrometry-based Proteomic profiling of lung cancer. Proc Am Thorac Soc 2009; 6(2):159-170.
12. Rosty C, Christa L, Kuzdzal S, et al.: Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res 2002; 62:1868-1875. (Pubitemid 34408515)
13. Petricoin EF, Ardekani AM, Hitt BA, et al.: Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359:572-577. (Pubitemid 34178440)
14. Adam BL, Qu Y, Davis JW, et al.: Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002; 62:3609-3614. (Pubitemid 34728833)
15. Vlahou A, Schellhammer PF, Mendrinos S, et al.: Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol 2001; 158:1491-1502. (Pubitemid 32281313)
16. De Noo ME, Tollenaar RA, Deelder AM, et al.: Current status and prospects of clinical proteomics studies on detection of colorectal cancer: hopes and fears. World J Gastroenterol 2006; 12:6594-6601. (Pubitemid 44794934)
17. Yuan Y, Tan CW, Shen H, et al.: Identification of the biomarkers for the prediction of efficacy in first-line chemotherapy of metastatic colorectal cancer patients using SELDI-TOF-MS and artificial neural networks. Hepatogastroenterology 2012; 59(120):2461-2465.
18. Eisenhauer EA, Therasse P, Bogaerts J, et al.: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247.
19. Bang YJ: Adjuvant XELOX shows promise in gastric cancer based on improvements in disease free survival [EB/OL]. 2011; [http://chicago2011.asco. org/ASCODailyNews/LBA40002]
20. Sakuramoto S, Sasako M, Yamaguchi T, et al.: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357(18):1810-1820. (Pubitemid 350044801)
21. Cavanna L, Artioli F, Codignola C: Oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic gastric cancer (MCC). Am J Clin Oncol 2006; 29(4):371-375. (Pubitemid 44201990)
22. Baek YH, Choi SR, Jang JS, et al.: Modified FOLFOX-4 as first-line and salvage treatment in advanced gastric cancer. Hepatogastroenterol 2011; 58(105):251-256.
23. Li XD, Shen H, Jiang JT, et al.: Paclitaxel based vs. oxaliplatin based regimens for advanced gastric cancer. World J Gastroenterol 2011; 17(8):1082-1087.
24. Lim JY, Cho JY, Paik YH, et al.: Diagnostic application of serum proteomic patterns in gastric cancer patients by Protein-Chip surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Int J Biol Markers 2007; 22(4):281-286. (Pubitemid 351256264)
25. Lu HB, Zhou JH, Ma YY, et al.: Five serum proteins identified using SELDI-TOF-MS as potential biomarkers of gastric cancer. Jpn J Clin Oncol 2010; 40(4):336-342.
26. Qian J, Li F, Yu J, et al.: Mining predictive biomarker for neoadjuvant chemotherapy in gastric cancer by proteomics. Hepatogastroenterology 2011; 58(110-111):1828-1833.
27. Teng KY, Qiu MZ, Li ZH, et al.: DNA polymerase η protein expression predicts treatment response and survival of metastaticgastric adenocarcinoma patients treated with oxaliplatin-based chemotherapy. J Transl Med 2010; 8:126.
28. Van Cutsem E, Kang Y, Chung H, et al.: Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol 2009; 27:18s (suppl; abstr LBA4509).
29. De Vita F, Giuliani F, Silvestris N, et al.: Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target. Cancer Treat Rev 2010; 36(Suppl 3):S11-15.
30. Garrisi VM, Bongarzone I, Mangia A, et al.: Characterization of a serum protein pattern from NSCLC patients treated with Gefitinib. Clin Biochem 2011; 44(10-11):936-940.